pluripotent

(redirected from Pluripotency)
Also found in: Medical, Wikipedia.

plu·rip·o·tent

 (plə-rĭp′ə-tənt)
adj.
Relating to or being a cell that is capable of differentiating into cells of any type of tissue except placental tissue.

[Latin plūs, plūr-, more, many; see pelə- in Indo-European roots + potent.]

plu·rip′o·ten·cy (-tən-sē) n.

pluripotent

(ˌplʊrɪˈpəʊtənt)
adj
(Biology) biology capable of differentiating into different types of body cell
Translations

plu·rip·o·tent

, pluripotential
a. pluripotencial, que puede tomar más de un curso de acción.
References in periodicals archive ?
The epigenetic events modulated by rigosertib in combination with either agent resulted in global histone post-translational modifications, differential Pol II association with active histone marks, epigenetic reprogramming of pluripotency genes, and expansion of primitive hematopoietic pluripotent stem cells.
CRISPR-Based Chromatin Remodeling of the Endogenous Oct4 or Sox2 Locus Enables Reprogramming to Pluripotency," Cell Stem Cell, 2018; DOI: 10.
The OCT4, an important transcription factor responsible for sternness, is a main regulator of pluripotency and self-renewal retaining in the Embryonic Stem (ES) and Embryonic Carcinoma (EC) cells (1-3).
Removing the methyl tags from the DNA, called demethylation, is a central part of achieving pluripotency and wiping epigenetic memory.
As described in the paper, the research team used sc-GEM to assay human fibroblasts undergoing reprogramming to pluripotency and primary lung adenocarcinoma cells and revealed important cell-to-cell differences in both.
Once established in vitro, ESCs can be cultured indefinitely without losing their pluripotency, and have the capacity to develop into any cell type in the body, and self-renewal (Okita and Yamanaka, 2006).
In February 2014, researchers claimed to have found a simple method of generating stem cells, by exposing adult cells to an acid bath; a method which they named stimulus-triggered acquisition of pluripotency (STAP).
Based on ideas and concepts linking cell pluripotency with metastatic and aggressive cancers, CureMeta is building a platform of potential cancer drug therapies through targeted antibody drug conjugates.
Cancer, biology, and genetics researchers from North America and Europe discuss the MYC protein and its regulation of expression, protein-protein interactions, genomic recognition, and transcriptional functions; MYC's biological activities in normal cellular processes, including its roles in pluripotency, vertebrate and invertebrate development, DNA replication, apoptosis, and metabolism; the activities that make it a major driver in oncogenicity, including its regulatory mutations, induction of genomic instability, cell competition, and metabolic programming; specific examples of its roles in Burkitt lymphoma, medulloblastoma, and neuroblastoma; and approaches to tumors, including synthetic lethal screens and targeted chemotherapy.
After a five-month investigation by the Riken Center for Developmental Biology of two stress-triggered acquisition of pluripotency (STAP) cell studies in the journal Nature, the papers were retracted in early July.
The retraction states: "These multiple errors impair the credibility of the study as a whole and we are unable to say without doubt whether the stimulus-triggered acquisition of pluripotency stem cells phenomenon is real.
In fact, one of the co-authors of the study had also called for a retraction in March, because he questioned some of the data that were used in the experiments, which led to the creation of so-called STAP cells (or stimulus-triggered acquisition of pluripotency cells).